Geode Capital Management LLC Purchases 1,399 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

Geode Capital Management LLC grew its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS) by 1.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 86,322 shares of the company’s stock after purchasing an additional 1,399 shares during the quarter. Geode Capital Management LLC owned approximately 0.10% of NewAmsterdam Pharma worth $1,433,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of NAMS. Frazier Life Sciences Management L.P. grew its position in NewAmsterdam Pharma by 5.1% during the third quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company’s stock valued at $213,396,000 after acquiring an additional 628,251 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of NewAmsterdam Pharma by 51.1% in the 3rd quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company’s stock valued at $25,607,000 after purchasing an additional 520,772 shares in the last quarter. Millennium Management LLC grew its holdings in shares of NewAmsterdam Pharma by 23.0% during the 2nd quarter. Millennium Management LLC now owns 1,165,429 shares of the company’s stock valued at $22,388,000 after purchasing an additional 217,902 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of NewAmsterdam Pharma by 8.9% during the 3rd quarter. Jennison Associates LLC now owns 1,020,278 shares of the company’s stock valued at $16,937,000 after purchasing an additional 83,115 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C raised its position in NewAmsterdam Pharma by 30.3% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 869,250 shares of the company’s stock worth $16,698,000 after purchasing an additional 202,250 shares during the period. 89.89% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at NewAmsterdam Pharma

In other news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the firm’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $25.02, for a total value of $213,420.60. Following the completion of the sale, the insider now directly owns 11,812,033 shares of the company’s stock, valued at approximately $295,537,065.66. This trade represents a 0.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last three months, insiders have sold 446,730 shares of company stock worth $11,438,695. 19.50% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

NAMS has been the subject of several analyst reports. HC Wainwright assumed coverage on shares of NewAmsterdam Pharma in a research report on Monday, December 30th. They set a “buy” rating and a $48.00 price target for the company. Piper Sandler restated an “overweight” rating and set a $37.00 target price on shares of NewAmsterdam Pharma in a report on Monday, September 23rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a research note on Thursday, December 5th. Finally, Scotiabank boosted their price objective on NewAmsterdam Pharma from $35.00 to $47.00 and gave the company a “sector outperform” rating in a research report on Wednesday, December 11th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, NewAmsterdam Pharma currently has a consensus rating of “Buy” and an average target price of $38.17.

NewAmsterdam Pharma Stock Performance

Shares of NASDAQ:NAMS opened at $25.55 on Friday. The stock’s 50-day moving average is $23.27 and its 200 day moving average is $19.64. NewAmsterdam Pharma has a 1 year low of $12.04 and a 1 year high of $27.29.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.